|
ARAF |
A-Raf proto-oncogene, serine/threonine kinase |
- RAF activation
- MAP2K and MAPK activation
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by MRAS-complex mutants
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
HIF1A |
hypoxia inducible factor 1 subunit alpha |
- Regulation of gene expression by Hypoxia-inducible Factor
- Cellular response to hypoxia
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- NOTCH1 Intracellular Domain Regulates Transcription
- Circadian Clock
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- PTK6 Expression
- PTK6 promotes HIF1A stabilization
- Neddylation
|
- Carvedilol
- Hydralazine
- 2-Methoxyestradiol
- ENMD-1198
- PX-478
- FG-2216
|
|
|
RPS6KA3 |
ribosomal protein S6 kinase A3 |
- ERK/MAPK targets
- CREB phosphorylation
- Senescence-Associated Secretory Phenotype (SASP)
- Senescence-Associated Secretory Phenotype (SASP)
- Recycling pathway of L1
- CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling
- RSK activation
- RSK activation
- Gastrin-CREB signalling pathway via PKC and MAPK
|
- Acetylsalicylic acid
- Fostamatinib
|
- Non-syndromic X-linked mental retardation
- Coffin-Lowry syndrome (CLS)
|
|
AURKA |
aurora kinase A |
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Regulation of PLK1 Activity at G2/M Transition
- SUMOylation of DNA replication proteins
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- Regulation of TP53 Activity through Phosphorylation
- FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
- AURKA Activation by TPX2
- Interaction between PHLDA1 and AURKA
|
- Phosphonothreonine
- AT9283
- CYC116
- Alisertib
- SNS-314
- Cenisertib
- Enzastaurin
- 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
- AKI-001
- 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea
- 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea
- N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE
- N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
- 2-(1H-pyrazol-3-yl)-1H-benzimidazole
- N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
- Fostamatinib
- MLN8054
|
|
|
CDK6 |
cyclin dependent kinase 6 |
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Cyclin D associated events in G1
- Regulation of RUNX1 Expression and Activity
- Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
- Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
|
- Alvocidib
- (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol
- Fisetin
- Palbociclib
- Ribociclib
- Abemaciclib
|
|
|
SMARCA4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
- Interleukin-7 signaling
- Formation of the beta-catenin:TCF transactivating complex
- RMTs methylate histone arginines
- Chromatin modifying enzymes
- RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
- EGR2 and SOX10-mediated initiation of Schwann cell myelination
- EGR2 and SOX10-mediated initiation of Schwann cell myelination
|
|
|
|
TNFRSF1A |
TNF receptor superfamily member 1A |
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
- TNFR1-mediated ceramide production
- TNFs bind their physiological receptors
- Interleukin-10 signaling
- TNF signaling
|
- 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One
- Tasonermin
|
- Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
|
|
ARNT |
aryl hydrocarbon receptor nuclear translocator |
- Regulation of gene expression by Hypoxia-inducible Factor
- PPARA activates gene expression
- Phase I - Functionalization of compounds
- Endogenous sterols
- Xenobiotics
- Aryl hydrocarbon receptor signalling
|
|
|
|
CD44 |
CD44 molecule (Indian blood group) |
- Degradation of the extracellular matrix
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Hyaluronan uptake and degradation
- Neutrophil degranulation
- Interferon gamma signaling
|
- Bivatuzumab
- Hyaluronic acid
|
|
|
EPHA2 |
EPH receptor A2 |
- EPH-Ephrin signaling
- EPH-Ephrin signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- EPH-ephrin mediated repulsion of cells
|
- Dasatinib
- Phosphoaminophosphonic Acid-Adenylate Ester
- Regorafenib
- Fostamatinib
|
|
|
HERC2 |
HECT and RLD domain containing E3 ubiquitin protein ligase 2 |
- SUMOylation of DNA damage response and repair proteins
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Nonhomologous End-Joining (NHEJ)
- Processing of DNA double-strand break ends
- G2/M DNA damage checkpoint
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
MAP2K6 |
mitogen-activated protein kinase kinase 6 |
- NOD1/2 Signaling Pathway
- Oxidative Stress Induced Senescence
- activated TAK1 mediates p38 MAPK activation
- Myogenesis
- PI5P Regulates TP53 Acetylation
- Interleukin-1 signaling
|
|
|
|
RASA1 |
RAS p21 protein activator 1 |
- Downstream signal transduction
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- VEGFR2 mediated cell proliferation
- Regulation of RAS by GAPs
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
|
- RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
|
|
SIRT1 |
sirtuin 1 |
- Regulation of HSF1-mediated heat shock response
- Circadian Clock
- SIRT1 negatively regulates rRNA expression
- SIRT1 negatively regulates rRNA expression
- Regulation of FOXO transcriptional activity by acetylation
- Regulation of FOXO transcriptional activity by acetylation
|
- Resveratrol
- Selisistat
- Cambinol
|
|
|
CDKN2B |
cyclin dependent kinase inhibitor 2B |
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- Oncogene Induced Senescence
- Cyclin D associated events in G1
|
|
- Malignant pleural mesothelioma
- Osteosarcoma
- Type II diabetes mellitus
|
|
CTSB |
cathepsin B |
- Collagen degradation
- Trafficking and processing of endosomal TLR
- Assembly of collagen fibrils and other multimeric structures
- MHC class II antigen presentation
- Neutrophil degranulation
|
- 2-Aminoethanimidic Acid
- 3-Amino-4-Oxybenzyl-2-Butanone
- 3-Methylphenylalanine
- N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline
- 2-Pyridinethiol
- Diphenylacetic acid
- N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane
- N-{[(2S,3S)-3-(Ethoxycarbonyl)-2-oxiranyl]carbonyl}-L-threonyl-L-isoleucine
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE
- BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
- METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE
- N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE
- N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE
|
- Tropical calcific pancreatitis
|
|
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
- Macroautophagy
- Energy dependent regulation of mTOR by LKB1-AMPK
- TP53 Regulates Metabolic Genes
- Regulation of TP53 Activity through Phosphorylation
- Activation of AMPK downstream of NMDARs
|
- Adenosine phosphate
- Adenosine phosphate
- ATP
- Phenformin
- Acetylsalicylic acid
- Fostamatinib
- Fostamatinib
|
|
|
RPS6KA5 |
ribosomal protein S6 kinase A5 |
- ERK/MAPK targets
- CREB phosphorylation
- NCAM signaling for neurite out-growth
- Recycling pathway of L1
- CD209 (DC-SIGN) signaling
|
|
|
|
TSG101 |
tumor susceptibility 101 |
- Budding and maturation of HIV virion
- Membrane binding and targetting of GAG proteins
- Endosomal Sorting Complex Required For Transport (ESCRT)
- HCMV Late Events
- Late endosomal microautophagy
|
|
|
|
ALDOB |
aldolase, fructose-bisphosphate B |
- Hereditary fructose intolerance
- Glycolysis
- Gluconeogenesis
- Fructose catabolism
|
- 1,6-Fructose Diphosphate (Linear Form)
- sn-glycerol 3-phosphate
- Dihydroxyacetone phosphate
|
- Hereditary fructose intolerance; Fructosemia
|